PFE Pfizer Inc.
Mid-channel
Price is between the two trend lines. Nothing to act on yet.
- Lower line today
- US$22.21
- Upper line today
- US$27.84
- Position in channel
- 50%
- Trend
- Sideways channel
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line
- Lower trend line
- Projected 3 months
Suggested path
Buy at or below
US$24.25
level as at 24 Aug 2026
Target
US$25.70
by 17 Sept 2026
Projected move
6.0%
gross, before costs
The lines are drawn where this stock has actually turned: 7 touches on the ceiling, 6 on the floor, each fitted to the slope that catches the most of them. Buying one average daily range below its 50-day mean, while it is still above its 200-day mean, and taking 6% has come up 783 times, 64% of them reaching the target, typically in 24 days, with price going about 7% against the entry at worst (35% in the worst case). This stock has not traded long enough to choose a plan of its own, so the levels come from the market-wide rule — derived on eight unrelated tickers and then confirmed on 87 others it was never fitted to, where it reached target 64% of the time. Treat it as the general setup applied here, not as this stock’s own record. On this stock the setup has come up 5 times so far, reaching target 60% of the time — too few to mean much on its own.
On this stock's own history these rules produced 5 settled calls, of which 3 reached target (60%), with an average best move of 5%. See the full record.
- Upper line touches
- 7
- Lower line touches
- 6
- Fit confidence
- 63%
- Fitted
- 2 Aug 2026
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla
- Employees
- 75,000
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- 79/100
- Profitability
- 48/100
- Financial health
- 42/100
- Cash generation
- 61/100
Key statistics
- Market cap
- US$142.54B
- Enterprise value
- US$205.29B
- Beta
- 0.31
- Avg volume
- 41.19M
- Revenue per share
- 11.13
- Dividend yield
- 6.88%
- 52-week range
- 23.4-28.75
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- 19.09
- PEG
- -3.32
- Price / sales
- 2.25
- Price / book
- 1.58
- EV / EBITDA
- 12.26
- Gross margin
- 69.35%
- Operating margin
- 23.45%
- Net margin
- 11.83%
- Current ratio
- 1.25
- Quick ratio
- 0.94
- Debt / equity
- 0.72
- Interest cover
- 5.53
Income statement
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | US$62.58B | US$44.01B | US$15.44B | US$7.77B | US$1.36 |
| 2024 | US$63.63B | US$41.85B | US$16.48B | US$8.02B | US$1.41 |
| 2023 | US$59.55B | US$30.34B | US$5.29B | US$2.13B | US$0.37 |
| 2022 | US$100.33B | US$62.09B | US$37.55B | US$31.36B | US$5.47 |
| 2021 | US$81.29B | US$46.88B | US$20.79B | US$22.15B | US$3.88 |
Balance sheet
| Year | Total assets | Total liabilities | Total equity |
|---|---|---|---|
| 2025 | US$208.16B | US$121.39B | US$86.48B |
| 2024 | US$213.40B | US$124.90B | US$88.20B |
| 2023 | US$226.50B | US$137.21B | US$89.01B |
| 2022 | US$197.21B | US$101.29B | US$95.66B |
| 2021 | US$181.48B | US$104.01B | US$77.20B |
Cash flow
| Year | Operating cash flow | Free cash flow | Net income |
|---|---|---|---|
| 2025 | US$11.71B | US$9.08B | US$7.75B |
| 2024 | US$12.74B | US$9.84B | US$8.05B |
| 2023 | US$8.70B | US$4.79B | US$2.17B |
| 2022 | US$29.27B | US$26.03B | US$31.40B |
| 2021 | US$32.58B | US$29.87B | US$22.46B |
EPS forecasts
| Period | Est. EPS | Est. revenue | Analysts |
|---|---|---|---|
| 2025 | US$3.12 | US$61.94B | 17 |
| 2026 | US$2.94 | US$61.78B | 14 |
| 2027 | US$2.84 | US$59.29B | 13 |
| 2028 | US$2.44 | US$54.74B | 6 |
| 2029 | US$2.30 | US$53.41B | 4 |
| 2030 | US$2.35 | US$53.80B | 2 |
Analyst view
- Target (mean)
- US$26.88
- Target (high)
- US$30.00
- Target (low)
- US$25.00
- Strong buy
- 0
- Buy
- 15
- Hold
- 23
- Sell
- 1
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.